Mesa establishes a presence in San Diego, where Agena’s headquarters and facility will continue to be maintained, as well as strengthening Agena’s other global offices and brands. With this acquisition, we expect that over 90% of future revenues will be generated from sales to biopharma, medical device, and healthcare service verticals,” said Gary Owens, President and Chief Executive Officer of Mesa. “The acquisition of Agena is another critical step in redirecting the strategic trajectory of Mesa toward higher growth applications within the regulated segments of the life sciences tools market.
Together, Mesa and Agena will join to pursue the common purpose of Protecting the Vulnerable®.Īgena is a leading clinical genomics tools company that develops, manufactures, and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions to clinical labs and development partners globally. With this highly strategic acquisition, Agena’s innovative approach to molecular diagnostics is now paired with Mesa’s proven approach to continuous improvement and operational and commercial efficiency. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc. 20, 2021 (GLOBE NEWSWIRE) - Mesa Laboratories, Inc.
0 kommentar(er)
